Clinical trial
A Single Arm Uncontrolled 12 Months Clinical Study to Evaluate the Safety and Efficacy of Miglustat (Zavesca) for the Treatment of Niemann Pick Type C Disease (NPC) in Chinese Subjects
NCT03910621 is registered in ClinicalTrials.gov with Actelion as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single Arm Uncontrolled 12 Months Clinical Study to Evaluate the Safety and Efficacy of Miglustat (Zavesca) for the Treatment of Niemann Pick Type C Disease (NPC) in Chinese Subjects
- Lead sponsor
- Actelion
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- April 2, 2020
- Completion date
- March 25, 2022
- Enrollment
- 17 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.